Genetic variants and risk of thyroid cancer among Iranian patients

References

1. Deandrea, M, Gallone, G, Veglio, M, Balsamo, A, Grassi, A, Sapelli, S, et al.. Thyroid cancer histotype changes as observed in a major general hospital in a 21-year period. J Endocrinol Invest 1997;20:52–8. https://doi.org/10.1007/bf03347976.Search in Google Scholar

2. Feldt-Rasmussen, U. Iodine and cancer. Thyroid 2001;11:483–6. https://doi.org/10.1089/105072501300176435.Search in Google Scholar

3. Kohler, BA, Ward, E, McCarthy, BJ, Schymura, MJ, Ries, LA, Eheman, C, et al.. Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011;103:714–36. https://doi.org/10.1093/jnci/djr077.Search in Google Scholar

4. Jemal, A, Bray, F, Center, MM, Ferlay, J, Ward, E, Forman, D. Global cancer statistics. CA A Cancer J Clin 2011;61:69–90. https://doi.org/10.3322/caac.20107.Search in Google Scholar

5. Chen, AY, Jemal, A, Ward, EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer: Interdiscipl Int J Am Cancer Soc 2009;115:3801–7. https://doi.org/10.1002/cncr.24416.Search in Google Scholar

6. Segev, DL, Umbricht, C, Zeiger, MA. Molecular pathogenesis of thyroid cancer. Surg Oncol 2003;12:69–90. https://doi.org/10.1016/s0960-7404(03)00037-9.Search in Google Scholar

7. Torlontano, M, Attard, M, Crocetti, U, Tumino, S, Bruno, R, Costante, G, et al.. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metabol 2004;89:3402–7. https://doi.org/10.1210/jc.2003-031521.Search in Google Scholar PubMed

8. Xu, L, Port, M, Landi, S, Gemignani, F, Cipollini, M, Elisei, R, et al.. Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case–control studies. Thyroid: Off J Am Thyroid Assoc 2014;24:966–74. https://doi.org/10.1089/thy.2013.0566Search in Google Scholar PubMed PubMed Central

9. Oberman, B, Khaku, A, Camacho, F, Goldenberg, D. Relationship between obesity, diabetes and the risk of thyroid cancer. Am J Otolaryngol 2015;36:535–41. https://doi.org/10.1016/j.amjoto.2015.02.015.Search in Google Scholar PubMed

10. Bann, DV, Goyal, N, Camacho, F, Goldenberg, D. Increasing incidence of thyroid cancer in the Commonwealth of Pennsylvania. JAMA Otolaryngol Head Neck Surg 2014;140:1149–56. https://doi.org/10.1001/jamaoto.2014.1709.Search in Google Scholar PubMed PubMed Central

11. Lehrer, S, Rosenzweig, KE. Cold climate is a risk factor for thyroid cancer. Clin Thyroidol 2014;26:273–6. https://doi.org/10.1089/ct.2014;26.273-276.Search in Google Scholar

12. Memon, A, De Gonzalez, AB, Luqmani, Y, Suresh, A. Family history of benign thyroid disease and cancer and risk of thyroid cancer. Eur J Canc 2004;40:754–60. https://doi.org/10.1016/j.ejca.2003.12.011.Search in Google Scholar

13. Ma, J, Huang, M, Wang, L, Ye, W, Tong, Y, Wang, H. Obesity and risk of thyroid cancer: evidence from a meta-analysis of 21 observational studies. Med Sci Mon Int Med J Exp Clin Res 2015;21:283.10.12659/MSM.892035Search in Google Scholar

14. Hong, K-S, Son, J-W, Ryu, OH, Choi, M-G, Hong, JY, Lee, SJ. Cardiac effects of thyrotropin oversuppression with levothyroxine in young women with differentiated thyroid cancer. Int J Endocrinol 2016;2016:6. doi:https://doi.org/10.1155/2016/9846790.Search in Google Scholar

15. Khayamzadeh, M, Khayamzadeh, M, Tadayon, N, Salmanian, R, Zham, H, Razzaghi, Z, et al.. Survival of thyroid cancer and social determinants in Iran. Asian Pac J Cancer Prev 2011;12:95–8.Search in Google Scholar

16. Karkoobi, Y, Moradi, G, Sharifi, P, Ghafoori, S. Assessment of thyroid cancer risk factors in Kurdistan province. Sci J Kurdistan Univ Med Sci 2018;23:10–8.Search in Google Scholar

17. Morris, LG, Myssiorek, D. Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am J Surg 2010;200:454–61. https://doi.org/10.1016/j.amjsurg.2009.11.008.Search in Google Scholar

18. Davies, L, Welch, HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014;140:317–22. https://doi.org/10.1001/jamaoto.2014.1.Search in Google Scholar

19. Erichsen, HC, Chanock, SJ. SNPs in cancer research and treatment. Br J Canc 2004;90:747–51. https://doi.org/10.1038/sj.bjc.6601574.Search in Google Scholar

20. Mehta, RG, Mehta, RR. Vitamin D and cancer. J Nutr Biochem 2002;13:252–64. https://doi.org/10.1016/s0955-2863(02)00183-3.Search in Google Scholar

21. Ordonez-Moran, P, Larriba, MJ, Pendas-Franco, N, Aguilera, O, Gonzalez-Sancho, JM, Munoz, A. Vitamin D and cancer: an update of in vitro and in vivo data. Front Biosci 2005;10:2723–49. https://doi.org/10.2741/1731.Search in Google Scholar

22. Slattery, ML. Vitamin D receptor gene (VDR) associations with cancer. Nutr Rev 2007;65:S102–S4. https://doi.org/10.1301/nr.2007.aug.s102-s104.Search in Google Scholar

23. Hutchinson, PE, Osborne, JE, Lear, JT, Smith, AG, Bowers, PW, Morris, PN, et al.. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Canc Res 2000;6:498–504.Search in Google Scholar

24. Ntais, C, Polycarpou, A, Ioannidis, JPA. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomark Prev 2003;12:1395–402.Search in Google Scholar

25. Ye, WZ, Reis, AF, Velho, G. Identification of a novel Tru9 I polymorphism in the human vitamin D receptor gene. J Hum Genet 2000;45:56–7. https://doi.org/10.1007/s100380050011.Search in Google Scholar

26. Penna-Martinez, M, Ramos-Lopez, E, Stern, J, Hinsch, N, Hansmann, M-L, Selkinski, I, et al.. Vitamin D receptor polymorphisms in differentiated thyroid carcinoma. Thyroid : Off J Am Thyroid Assoc 2009;19:623–8. https://doi.org/10.1089/thy.2008.0388.Search in Google Scholar

27. Haghpanah, V, Ghaffari, SH, Rahimpour, P, Abbasi, A, Saeedi, M, Pak, H, et al.. Vitamin D receptor gene polymorphisms in patients with thyroid cancer. Gene Ther Mol Biol B 2007;11:299–304.Search in Google Scholar

28. Horvatic Herceg, G, Herceg, D, Kralik, M, Kulic, A, Bence-Zigman, Z, Tomic-Brzac, H, et al.. Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients. Otolaryngology-Head Neck Surg (Tokyo) 2013;149:533–40. https://doi.org/10.1177/0194599813496374.Search in Google Scholar

29. Ulisse, S, Baldini, E, Sorrenti, S, Barollo, S, Gnessi, L, Catania, A, et al.. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. J Clin Endocrinol Metabol 2011;96:504–8. https://doi.org/10.1210/jc.2010-1688.Search in Google Scholar

30. Mashiko, S, Kitatani, K, Toyoshima, M, Ichimura, A, Dan, T, Usui, T, et al.. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer. Canc Biol Ther 2015;16:253–60. https://doi.org/10.1080/15384047.2014.1001271.Search in Google Scholar

31. Torres-Carrillo, N, Magdalena Torres-Carrillo, N, Vázquez-Del Mercado, M, Rangel-Villalobos, H, Parra-Rojas, I, Sánchez-Enríquez, S, et al.. Distribution of --844 G/A and Hind III C/G PAI-1 polymorphisms and plasma PAI-1 levels in Mexican subjects: comparison of frequencies between populations. Clin Appl Thromb Hemost 2008;14:220–6. https://doi.org/10.1177/1076029607304747.Search in Google Scholar

32. Palmirotta, R, Ferroni, P, Savonarola, A, Martini, F, Ciatti, F, Laudisi, A, et al.. Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res 2009;124:403–8. https://doi.org/10.1016/j.thromres.2009.02.014.Search in Google Scholar

33. Zhang, H, Dong, P, Yang, X, Liu, Z. Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with coronary artery disease risk: a meta-analysis. Int J Clin Exp Med 2014;7:3777–88.Search in Google Scholar

34. Lewy-Trenda, I. Estrogen and progesterone receptors in neoplastic and non-neoplastic thyroid lesions. Pol J Pathol 2002;53:67–72.Search in Google Scholar

35. Money, SR, Muss, W, Thelmo, WL, Boeckl, O, Pimpl, W, Kaindl, H, et al.. Immunocytochemical localization of estrogen and progesterone receptors in human thyroid. Surgery 1989;106:975–9.Search in Google Scholar

36. Mazzaferri, EL, Young, RL, Oertel, JE, Kemmerer, WT, Page, CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltim) 1977;56:171–96. https://doi.org/10.1097/00005792-197705000-00001.Search in Google Scholar

37. Liu, J, Chen, G, Meng, X-Y, Liu, Z-H, Dong, S. Serum levels of sex hormones and expression of their receptors in thyroid tissue in female patients with various types of thyroid neoplasms. Pathol Res Pract 2014;210:830–5. https://doi.org/10.1016/j.prp.2014.09.002.Search in Google Scholar

38. Vasudevan, N, Ogawa, S, Pfaff, D. Estrogen and thyroid hormone receptor interactions: physiological flexibility by molecular specificity. Physiol Rev 2002;82:923–44. https://doi.org/10.1152/physrev.00014.2002.Search in Google Scholar

39. Shick, PC, Riordan, GP, Foss, RD. Estrogen and progesterone receptors in salivary gland adenoid cystic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80:440–4. https://doi.org/10.1016/s1079-2104(05)80338-5.Search in Google Scholar

40. Varley, JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003;21:313–20. https://doi.org/10.1002/humu.10185.Search in Google Scholar PubMed

41. Noma, C, Miyoshi, Y, Taguchi, T, Tamaki, Y, Noguchi, S. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Canc Lett 2004;210:197–203. https://doi.org/10.1016/j.canlet.2004.03.031.Search in Google Scholar PubMed

42. Pietsch, E, Humbey, O. Polymorphisms in the p53 pathway. Philadelphia, PA, USA: Division of Medical Science, Fox Chase Cancer Center; 2006.10.1038/sj.onc.1209367Search in Google Scholar PubMed

43. Khadang, B, Fattahi, MJ, Talei, A, Dehaghani, AS, Ghaderi, A. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Canc Genet Cytogenet 2007;173:38–42. https://doi.org/10.1016/j.cancergencyto.2006.09.010.Search in Google Scholar PubMed

44. Boltze, C, Roessner, A, Landt, O, Szibor, R, Peters, B, Schneider-Stock, R. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. Int J Oncol 2002;21:1151–4.10.3892/ijo.21.5.1151Search in Google Scholar

45. Granja, F, Morari, J, Morari, EC, Correa, LAC, Assumpção, LVM, Ward, LS. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Canc Lett 2004;210:151–7. https://doi.org/10.1016/j.canlet.2004.01.016.Search in Google Scholar PubMed

46. Aral, C, Akkiprik, M, Kaya, H, Ataizi-Çelikel, C, Caglayan, S, Ozisik, G, et al.. Mitochondrial DNA common deletion is not associated with thyroid, breast and colorectal tumors in Turkish patients. Genet Mol Biol 2010;33:1–4. https://doi.org/10.1590/S1415-47572009005000102.Search in Google Scholar PubMed PubMed Central

47. Reis, AAS, Silva, DM, Curado, MP, da Cruz, AD. Involvement of CYP1A1, GST, 72TP53 polymorphisms in the pathogenesis of thyroid nodules. Genet Mol Res 2010;9:2222–9. https://doi.org/10.4238/vol9-4gmr807.Search in Google Scholar PubMed

48. Landers, JE, Cassel, SL, George, DL. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Canc Res 1997;57:3562–8.Search in Google Scholar

49. Wade, M, Wang, YV, Wahl, GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 2010;20:299–309. https://doi.org/10.1016/j.tcb.2010.01.009.Search in Google Scholar PubMed PubMed Central

50. Wynendaele, J, Böhnke, A, Leucci, E, Nielsen, SJ, Lambertz, I, Hammer, S, et al.. An illegitimate microRNA target site within the 3’ UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Canc Res 2010;70:9641–9. https://doi.org/10.1158/0008-5472.can-10-0527.Search in Google Scholar

51. McEvoy, J, Ulyanov, A, Brennan, R, Wu, G, Pounds, S, Zhang, J, et al.. Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PloS One 2012;7:e42739-e. https://doi.org/10.1371/journal.pone.0042739.Search in Google Scholar PubMed PubMed Central

52. Eischen, CM, Lozano, G. The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat 2014;35:728–37. https://doi.org/10.1002/humu.22524.Search in Google Scholar PubMed PubMed Central

53. Senturk, E, Manfredi, JJ. Mdm2 and tumorigenesis: evolving theories and unsolved mysteries. Gene Canc 2012;3:192–8. https://doi.org/10.1177/1947601912457368.Search in Google Scholar PubMed PubMed Central

54. Thomasova, D, Mulay, SR, Bruns, H, Anders, H-J. p53-independent roles of MDM2 in NF-κB signaling: implications for cancer therapy, wound healing, and autoimmune diseases. Neoplasia 2012;14:1097–101. https://doi.org/10.1593/neo.121534.Search in Google Scholar PubMed PubMed Central

55. Zhang, F, Xu, L, Wei, Q, Song, X, Sturgis, EM, Li, G. Significance of MDM2 and P14ARF polymorphisms in susceptibility to differentiated thyroid carcinoma. Surgery 2013;153:711–7. https://doi.org/10.1016/j.surg.2012.11.009.Search in Google Scholar PubMed PubMed Central

56. Altieri, DC. Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 2003;5:447–52.10.1016/S0065-230X(03)88303-3Search in Google Scholar

57. Altieri, DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581. https://doi.org/10.1038/sj.onc.1207113.Search in Google Scholar PubMed

58. Li, F. Role of survivin and its splice variants in tumorigenesis. Br J Canc 2005;92:212. https://doi.org/10.1038/sj.bjc.6602340.Search in Google Scholar PubMed PubMed Central

59. Tirrò, E, Consoli, ML, Massimino, M, Manzella, L, Frasca, F, Sciacca, L, et al.. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Canc Res 2006;66:4263–72. https://doi.org/10.1158/0008-5472.can-05-3248.Search in Google Scholar PubMed

60. Selemetjev, SA, Savin, SB, Paunovic, IR, Tatic, SB, Cvejic, D. Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance. Wien Klin Wochenschr 2015;127:337–44. https://doi.org/10.1007/s00508-014-0674-6.Search in Google Scholar PubMed

61. Chen, Z, Liu, N, Zhu, G, Dralle, H, Hoang-Vu, C. Targeting of the anti-apoptotic gene survivin in human thyroid carcinoma. Int J Mol Med 2012;30:465–72. https://doi.org/10.3892/ijmm.2012.1046.Search in Google Scholar PubMed PubMed Central

62. Pannone, G, Santoro, A, Pasquali, D, Zamparese, R, Mattoni, M, Russo, G, et al.. The role of survivin in thyroid tumors: differences of expression in well-differentiated, non–well-differentiated, and anaplastic thyroid cancers. Thyroid 2014;24:511–9. https://doi.org/10.1089/thy.2013.0196.Search in Google Scholar PubMed

63. Mahaney, BL, Meek, K, Lees-Miller, SP. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J 2009;417:639–50. https://doi.org/10.1042/bj20080413.Search in Google Scholar

64. Mani, RS, Yu, Y, Fang, S, Lu, M, Fanta, M, Zolner, AE, et al.. Dual modes of interaction between XRCC4 and polynucleotide kinase/phosphatase implications for nonhomologous end joining. J Biol Chem 2010;285:37619–29. https://doi.org/10.1074/jbc.m109.058719.Search in Google Scholar

65. Siraj, A, Al-Rasheed, M, Ibrahim, M, Siddiqui, K, Al-Dayel, F, Al-Sanea, O, et al.. RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population. J Endocrinol Invest 2008;31:893–9. https://doi.org/10.1007/bf03346438.Search in Google Scholar PubMed

66. Gomes, BC, Silva, SN, Azevedo, AP, Manita, I, Gil, OM, Ferreira, TC, et al.. The role of common variants of non-homologous end-joining repair genes XRCC4, LIG4 and Ku80 in thyroid cancer risk. Oncol Rep 2010;24:1079–85.Search in Google Scholar

67. Chiang, F-Y, Wu, C-W, Hsiao, P-J, Kuo, W-R, Lee, K-W, Lin, J-C, et al.. Association between polymorphisms in DNA base excision repair genes XRCC1, APE1, and ADPRT and differentiated thyroid carcinoma. Clin Canc Res 2008;14:5919–24. https://doi.org/10.1158/1078-0432.ccr-08-0906.Search in Google Scholar PubMed

68. Zhu, Q, Bian, J, Shen, Q, Jiang, F, Tang, H, Zhang, H, et al.. Genetic polymorphisms in X-ray repair cross-complementing gene 1 and susceptibility to papillary thyroid carcinoma. Zhonghua Liuxingbingxue Zazhi 2004;25:702–5.Search in Google Scholar

69. Ho, T, Li, G, Lu, J, Zhao, C, Wei, Q, Sturgis, EM. Association of XRCC1 polymorphisms and risk of differentiated thyroid carcinoma: a case–control analysis. Thyroid 2009;19:129–35. https://doi.org/10.1089/thy.2008.0153.Search in Google Scholar PubMed

70. Ryu, RA, Tae, K, Min, HJ, Jeong, JH, Cho, SH, Lee, SH, et al.. XRCC1 polymorphisms and risk of papillary thyroid carcinoma in a Korean sample. J Kor Med Sci 2011;26:991–5. https://doi.org/10.3346/jkms.2011.26.8.991.Search in Google Scholar PubMed PubMed Central

71. Okamura, H, Tsutsui, H, Komatsu, T, Yutsudo, M, Hakura, A, Tanimoto, T, et al.. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995;378:88. https://doi.org/10.1038/378088a0.Search in Google Scholar PubMed

72. Takiyama, Y, Miyokawa, N, Tokusashi, Y, Ito, K, Kato, S, Kimura, S, et al.. Thyroid-stimulating hormone induces interleukin-18 gene expression in FRTL-5 cells: immunohistochemical detection of interleukin-18 in autoimmune thyroid disease. Thyroid 2002;12:935–43. https://doi.org/10.1089/105072502320908268.Search in Google Scholar PubMed

73. Liu, Z, Wang, H, Xiao, W, Wang, C, Liu, G, Hong, T. Thyrocyte interleukin‐18 expression is up‐regulated by interferon‐γ and may contribute to thyroid destruction in Hashimoto’s thyroiditis. Int J Exp Pathol 2010;91:420–5. https://doi.org/10.1111/j.1365-2613.2010.00715.x.Search in Google Scholar PubMed PubMed Central

74. Kalina, U, Ballas, K, Koyama, N, Kauschat, D, Miething, C, Arnemann, J, et al.. Genomic organization and regulation of the human interleukin‐18 gene: FRONTLINES. Scand J Immunol 2000;52:525–30. https://doi.org/10.1046/j.1365-3083.2000.00836.x.Search in Google Scholar

75. Giedraitis, V, He, B, Huang, W-X, Hillert, J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 2001;112:146–52. https://doi.org/10.1016/s0165-5728(00)00407-0.Search in Google Scholar

76. Haghshenas, MR, Hosseini, SV, Mahmoudi, M, Saberi‐Firozi, M, Farjadian, S, Ghaderi, A. IL‐18 serum level and IL‐18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. J Gastroenterol Hepatol 2009;24:1119–22. https://doi.org/10.1111/j.1440-1746.2009.05791.x.Search in Google Scholar PubMed

77. Razmkhah, M, Doroudchi, M, Mojtahedi, Z, Ghaderi, A. Association of Interleukin18 gene promoter polymorphisms with breast cancer. Neoplasma 2009;56:1.10.4149/neo_2009_01_22Search in Google Scholar

78. Farjadfar, A, Mojtahedi, Z, Ghayumi, MA, Erfani, N, Haghshenas, MR, Ghaderi, A. Interleukin-18 promoter polymorphism is associated with lung cancer: a case-control study. Acta Oncol 2009;48:971–6. https://doi.org/10.1080/02841860902878145.Search in Google Scholar PubMed

79. Walker, LS, Sansom, DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011;11:852. https://doi.org/10.1038/nri3108.Search in Google Scholar PubMed

80. Ghaderi, A. CTLA4 gene variants in autoimmunity and cancer: a comparative review. Iran J Immunol 2011;8:127–49.Search in Google Scholar

81. Karabon, L, Kosmaczewska, A, Bilinska, M, Pawlak, E, Ciszak, L, Jedynak, A, et al.. The CTLA‐4 gene polymorphisms are associated with CTLA‐4 protein expression levels in multiple sclerosis patients and with susceptibility to disease. Immunology 2009;128:e787–e96. https://doi.org/10.1111/j.1365-2567.2009.03083.x.Search in Google Scholar PubMed PubMed Central

82. Ligers, A, Teleshova, N, Masterman, T, Huang, W, Hillert, J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Gene Immun 2001;2:145. https://doi.org/10.1038/sj.gene.6363752.Search in Google Scholar PubMed

83. Chang, D-F, Chen, X-H, Huang, J, Sun, Y-M, Zhu, D-Y, Xu, Z-Q. CTLA-4 gene polymorphisms associate with efficacy of postoperative radioiodine-131 for differentiated thyroid carcinoma. Future Oncol 2017;13:1057–68. https://doi.org/10.2217/fon-2016-0399.Search in Google Scholar PubMed

84. Okazaki, T, Maeda, A, Nishimura, H, Kurosaki, T, Honjo, T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci 2001 98:13866–71. https://doi.org/10.1073/pnas.231486598.Search in Google Scholar PubMed PubMed Central

85. French, JD, Kotnis, GR, Said, S, Raeburn, CD, McIntyre, RCJr, Klopper, JP, et al.. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metabol 2012;97:E934–E43. https://doi.org/10.1210/jc.2011-3428.Search in Google Scholar PubMed PubMed Central

86. Mojtahedi, Z, Mohmedi, M, Rahimifar, S, Erfani, N, Hosseini, SV, Ghaderi, A. Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with colon cancer. Gene 2012;508:229–32. https://doi.org/10.1016/j.gene.2012.07.059.Search in Google Scholar PubMed

87. Mojtahedi, Z, Erfani, N, Haghshenas, MR, Hosseini, SV, Ghaderi, A. Association of FoxP3/Scurfin germline polymorphism (C-2383T/rs3761549) with colorectal cancer. Ann Colorectal Res 2013;1:12–6. https://doi.org/10.17795/acr-11478.Search in Google Scholar

88. Song, X, Zhong, H, Wu, Q, Wang, M, Zhou, J, Zhou, Y, et al.. Association between SNPs in microRNA machinery genes and gastric cancer susceptibility, invasion, and metastasis in Chinese Han population. Oncotarget 2017;8:86435. https://doi.org/10.18632/oncotarget.21199.Search in Google Scholar PubMed PubMed Central

89. Erler, P, Keutgen, XM, Crowley, MJ, Zetoune, T, Kundel, A, Kleiman, D, et al.. Dicer expression and microRNA dysregulation associate with aggressive features in thyroid cancer. Surgery 2014;156:1342–50. https://doi.org/10.1016/j.surg.2014.08.007.Search in Google Scholar PubMed

90. Leaderer, D, Hoffman, AE, Zheng, T, Fu, A, Weidhaas, J, Paranjape, T, et al.. Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. Int J Mol Epidemiol Genet 2011;2:9.Search in Google Scholar

91. Wen, J, Gao, Q, Wang, N, Zhang, W, Cao, K, Zhang, Q, et al.. Association of microRNA-related gene XPO5 rs11077 polymorphism with susceptibility to thyroid cancer. Medicine (Baltim) 2017;96. https://doi.org/10.1097/md.0000000000006351.Search in Google Scholar PubMed PubMed Central

92. Tang, R, Yang, C, Ma, X, Wang, Y, Luo, D, Huang, C, et al.. MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in gastric cancer. Oncotarget 2016;7:5972. https://doi.org/10.18632/oncotarget.6821.Search in Google Scholar PubMed PubMed Central

93. Pan, W, Wu, C, Su, Z, Duan, Z, Li, L, Mi, F, et al.. Genetic polymorphisms of non-coding RNAs associated with increased head and neck cancer susceptibility: a systematic review and meta-analysis. Oncotarget 2017;8:62508. https://doi.org/10.18632/oncotarget.20096.Search in Google Scholar PubMed PubMed Central

94. Wang, Y, Wei, T, Xiong, J, Chen, P, Wang, X, Zhang, L, et al.. Association between genetic polymorphisms in the promoter regions of let-7 and risk of papillary thyroid carcinoma: a case-control study. Medicine (Baltim) 2015;94:e1879. doi:https://doi.org/10.1097/md.0000000000001879.Search in Google Scholar

95. He, J, Zou, Y, Liu, X, Zhu, J, Zhang, J, Zhang, R, et al.. Association of common genetic variants in pre-microRNAs and neuroblastoma susceptibility: a two-center study in Chinese children. Mol Ther Nucleic Acids 2018;11:1–8. https://doi.org/10.1016/j.omtn.2018.01.003.Search in Google Scholar PubMed PubMed Central

96. Hashemi, M. MicroRNAs: promising potential targets for cancer treatment. Gene Cell Tissue 2016;3:e42864. doi:https://doi.org/10.17795/gct-42864.Search in Google Scholar

97. Chen, P, Sun, R, Pu, Y, Bai, P, Yuan, F, Liang, Y, et al.. Pri-miR-34b/C and Tp-53 polymorphisms are associated with the susceptibility of papillary thyroid carcinoma: a case–control study. Medicine (Baltim) 2015;94. https://doi.org/10.1097/md.0000000000001536.Search in Google Scholar

98. Dehghan, R, Hosseinpour Feizi, MA, Pouladi, N, Adampourezare, M, Farajzadeh, D. The TP53 intron 6 G13964C polymorphism and risk of thyroid and breast cancer development in the Iranian Azeri population. Asian Pac J Cancer Prev 2015;16:3073–7. https://doi.org/10.7314/apjcp.2015.16.7.3073.Search in Google Scholar PubMed

99. Dehghan, R, Hosseinpour Feizi, MA, Pouladi, N, Babaei, E, Montazeri, V, Fakhrjoo, A, et al.. Association of p53 (-16ins-pro) haplotype with the decreased risk of differentiated thyroid carcinoma in Iranian-Azeri patients. Pathol Oncol Res 2015;21:449–54. https://doi.org/10.1007/s12253-014-9846-y.Search in Google Scholar PubMed

100. Fard-Esfahani, P, Fard-Esfahani, A, Fayaz, S, Ghanbarzadeh, B, Saidi, P, Mohabati, R, et al.. Association of Arg194Trp, Arg280His and Arg399Gln polymorphisms in X-ray repair cross-complementing group 1 gene and risk of differentiated thyroid carcinoma in Iran. Iran Biomed J 2011;15:73–8.Search in Google Scholar

101. Fard-Esfahani, P, Fard-Esfahani, A, Saidi, P, Fayaz, S, Mohabati, R, Majdi, M. An increased risk of differentiated thyroid carcinoma in Iran with the 677C -> T homozygous polymorphism in the MTHFR gene. Canc Epidemiol 2011;35:56–8. https://doi.org/10.1016/j.canep.2010.10.001.Search in Google Scholar PubMed

102. Rahimi, M, Fayaz, S, Fard-Esfahani, A, Modarressi, MH, Akrami, SM, Fard-Esfahani, P. The role of Ile3434Thr XRCC7 gene polymorphism in differentiated thyroid cancer risk in an Iranian population. Iran Biomed J 2012;16:218–22. https://doi.org/10.6091/ibj.1078.2012.Search in Google Scholar PubMed PubMed Central

103. Yazdani, N, Sayahpour, FA, Haghpanah, V, Amiri, P, Shahrabi-Farahani, M, Moradi, M, et al.. Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol Res Pract 2012;208:100–3. https://doi.org/10.1016/j.prp.2011.12.009.Search in Google Scholar PubMed

104. Hamta, A, Yousefi, M, FAZELI, MAM, Talaei, A, Sadeghi, A. Lack of association between nodular thyroid disease and rs1256049 polymorphism of estrogen receptor beta gene in women from Markazi povince. J Arak Uni Med Sci 2015;18:85–91.Search in Google Scholar

105. Feizi, MAH, Tofigh, R, Pouladi, N, Ravanbakhsh, R, Azarfam, P, Montazeri, V. The study of P53 polymorphism in codon 72 in patients with thyroid cancer in a report from East Azerbaijan province Iran. Med J Tabriz Univ Med Sci Health Serv 2013;35:24–9.Search in Google Scholar

106. Rahimi, M, Fard-Esfahani, P, Fayaz, S, Fard-Esfahani, A, Modarressi, MH, Akrami, SM. Analysis of G> A change in splicing site of intron 6 of XRCC4 gene in patients with differentiated thyroid cancer (DTC). Int Sportmed J (ISMJ) 2014;17:542–9.Search in Google Scholar

107. Younesi, M, Hosseinpour Feizi, M, Pouladi, N. Evaluating the prevalence of plasminogen activator inhibitor-1 gene polymorphism in patients with thyroid tumors from North West of Iran. J Ilam Univ Med Sci 2017;25:166–72. https://doi.org/10.29252/sjimu.25.2.166.Search in Google Scholar

108. Abidi, M, Fayaz, S, Esfahani, PF. Association of the Asp1312Gly thyroglobulin gene polymorphism with susceptibility to differentiated thyroid cancer in an Iranian population. Asian Pac J Cancer Prev APJCP 2017;18:503. https://doi.org/10.22034/APJCP.2017.18.2.503.Search in Google Scholar PubMed PubMed Central

109. Adampourezare, M, Hosseinpourefeizi, M-A, Pouladi, N, Hosseinpourefeizi, E, Azarfam, P. Association of Arg194Trp and Arg399Gln polymorphisms of XRCC1 gene and risk of differentiated thyroid carcinoma in Iranian-Azeri patients. Int J Canc Manag 2017;10. https://doi.org/10.5812/ijcm.5790.Search in Google Scholar

110. Ramezani, M, Hedayati, M, Hoseini Asl, S, Tabatabaei, M, Mazani, M, Nasiri, S. Association of vitamin D levels and receptor gene polymorphisms with medullary thyroid cancer. Tehran Univ Med J TUMS Publ 2016;74:274–81.Search in Google Scholar

111. Khanlou, ZM, Pouladi, N, Feizi, MH, Pedram, N. Lack of associations of the MDM4 rs4245739 polymorphism with risk of thyroid cancer among Iranian-Azeri patients: a case-control study. Asian Pac J Cancer Prev APJCP 2017;18:1133.Search in Google Scholar

112. Maruei-Milan, R, Heidari, Z, Salimi, S. Role of MDM2 309T>G (rs2279744) and I/D (rs3730485) polymorphisms and haplotypes in risk of papillary thyroid carcinoma, tumor stage, tumor size, and early onset of tumor: a case control study. J Cell Physiol 2019;234:12934–40. https://doi.org/10.1002/jcp.27960.Search in Google Scholar PubMed

113. Abdolahi, F, Dabbaghmanesh, MH, Haghshenas, MR, Ghaderi, A, Erfani, N. A gene-disease association study of IL18 in thyroid cancer: genotype and haplotype analyses. Endocrine 2015;50:698–707. https://doi.org/10.1007/s12020-015-0623-9.Search in Google Scholar PubMed

114. Abtahi, S, Jahromi, FI, Dabbaghmanesh, MH, Malekzadeh, M, Ghaderi, A. Association between CTLA-4+ 49A> G and–318C> T single-nucleotide polymorphisms and susceptibility to thyroid neoplasm. Endocrine 2018;62:159–65. https://doi.org/10.1007/s12020-018-1663-8.Search in Google Scholar PubMed

115. Fayaz, S, Karimmirza, M, Tanhaei, S, Fathi, M, Torbati, PM, Fard-Esfahani, P. Increased risk of differentiated thyroid carcinoma with combined effects of homologous recombination repair gene polymorphisms in an Iranian population. Asian Pac J Cancer Prev APJCP 2013;14:6727–31. https://doi.org/10.7314/apjcp.2013.14.11.6727.Search in Google Scholar PubMed

116. Haghshenas, M, Dabbaghmanesh, M, Miri, A, Ghaderi, A, Erfani, N. Association of PDCD1 gene markers with susceptibility to thyroid cancer. J Endocrinol Invest 2017;40:481–6. https://doi.org/10.1007/s40618-016-0579-5.Search in Google Scholar PubMed

117. Heidari, Z, Mohammadpour‐Gharehbagh, A, Eskandari, M, Harati‐Sadegh, M, Salimi, S. Genetic polymorphisms of miRNA let7a‐2 and pri‐mir‐34b/c are associated with an increased risk of papillary thyroid carcinoma and clinical/pathological features. J Cell Biochem 2019;120:8640–7. https://doi.org/10.1002/jcb.28152.Search in Google Scholar PubMed

118. Mohammadpour-Gharehbagh, A, Heidari, Z, Eskandari, M, Aryan, A, Salimi, S. Association between genetic polymorphisms in microRNA machinery genes and risk of papillary thyroid carcinoma. Pathol Oncol Res 2019:1–7.10.1007/s12253-019-00688-zSearch in Google Scholar PubMed

119. Narooie-Nejad, M, Taji, O, Kordi Tamandani, DM, Kaykhaei, MA. Association of CTLA-4 gene polymorphisms-318C/T and+ 49A/G and Hashimoto’s thyroiditis in Zahedan, Iran. Biomed Rep 2017;6:108–12. https://doi.org/10.3892/br.2016.813.Search in Google Scholar PubMed PubMed Central

120. Khoshi, A, Sirghani, A, Ghazisaeedi, M, Mahmudabadi, AZ, Azimian, A. Association between TPO Asn698Thr and Thr725Pro gene polymorphisms and serum anti-TPO levels in Iranian patients with subclinical hypothyroidism. Hormones (Basel) 2017;16:75–83.10.14310/horm.2002.1721Search in Google Scholar

121. Zarrin, R, Bagheri, M, Mehdizadeh, A, Ayremlou, P, Faghfouri, AH. The association of FokI and ApaI polymorphisms in vitamin D receptor gene with autoimmune thyroid diseases in the northwest of Iran. Med J Islam Repub Iran 2018;32:4. https://doi.org/10.14196/mjiri.32.4.Search in Google Scholar PubMed PubMed Central